GPT and Cholecystitis, Acute: Including supplemental laboratory data (measurements entered in the database from sources other than the central laboratory; primarily drawn during hospitalization), there were 16 patients in the omarigliptin group and 17 patients in the placebo group with ALT ≥5× ULN; all of the patients in the omarigliptin group had a plausible alternative explanation (e.g., acute cholecystitis, alcohol abuse, metastatic cancer) and/or resolved on study medication.